Oxygen Atom Of The Saccharide Radical Is Bonded To A Cyclohexyl Radical (e.g., Kasugamycin, Etc.) Patents (Class 435/79)
-
Patent number: 5798266Abstract: Non-invasive methods and kits are provided for obtaining biological samples of mammary fluid or mammary fluid components by administering oxytocin or an oxytocin analogue to a mammalian patient to stimulate expression of mammary fluid. The oxytocin is preferably administered intranasally and causes myoepithelial contraction of target alveolar-ductal tissues of the breast. During or after mammary fluid expression, a biological sample is collected in the form of whole mammary fluid, whole cells or cellular components, other selected liquid or solid fractions of the mammary fluid, purified or bulk proteins, glycoproteins, peptides, nucleotides or other desired constituents of mammary fluid. Methods and kits are also provided for determining the presence or amount of a breast disease marker in biological samples of mammary fluid or mammary fluid components.Type: GrantFiled: August 27, 1996Date of Patent: August 25, 1998Assignee: K-Quay Enterprises, LLCInventors: Steven C. Quay, Debra L. Quay
-
Patent number: 5798218Abstract: Aerolysin is shown to bind specifically to the Thy-1 antigen. Aerolysin-based methods, compositions and kits for detecting the presence of Thy-1 antigen are presented.Type: GrantFiled: September 24, 1996Date of Patent: August 25, 1998Assignee: University of British Columbia Innovation and Development CorporationInventor: James Thomas Buckley
-
Patent number: 5798205Abstract: A novel HIV type O immunodeficiency virus is disclosed which has the designation MVP-2901/94 and which has been deposited with the European Collection of Animal Cell Cultures (ECACC) under No. V 95012601. The characteristic antigens which can be obtained from the virus and which can be employed for detecting antibodies against retroviruses which are associated with immunodeficiency diseases are also disclosed, as are the partial DNA and amino acid sequences of the virus.Type: GrantFiled: February 16, 1996Date of Patent: August 25, 1998Assignee: Behringwerke AktiengesellschaftInventors: Hans-Peter Hauser, Stefan Knapp, Stefan Brust, Lutz G. Gurtler, Josef Eberle, Lazare Kaptue, Leopold Achenqui Zekeng
-
Patent number: 5798448Abstract: The present invention provides nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in preparing antibodies and in diagnosing and treating various neuronal disorders.Type: GrantFiled: May 15, 1995Date of Patent: August 25, 1998Assignee: Genentech, Inc.Inventors: Ingrid W. Caras, John W. Winslow
-
Patent number: 5798447Abstract: Antibodies against Ins(1,4,5)P.sub.3 were raised by immunizing rabbits with two types of IP.sub.3 -BSA conjugates which were synthesized by covalently coupling Ins(1,4,5)P.sub.3 to the carrier protein via alkyl linkages. The anti-Ins(1,4,5)P.sub.3 antibodies were detected by an ELISA where Ins(1,4,5)P.sub.3 was covalently attached to a microplate well surface. Both antiserum preparations showed specific binding with Ins(1,4,5)P.sub.3. The specificity of these antibodies was enhanced by affinity purification for the antiserum through Ins(1,4,5)P.sub.3 -agarose chromatography. The affinity-purified antibodies have IC.sub.50 values of 12 nM and 73OnM for Ins(1,4,5)P.sub.3 and Ins(1,3,4,5)P.sub.4, respectively. These antibodies showed many properties similar to those of biologically relevant receptors for Ins(1,4,5)P.sub.3.Type: GrantFiled: January 11, 1996Date of Patent: August 25, 1998Assignee: The Board of Governors for Higher Education State of Rhode Island and Providence PlantationsInventor: Ching-Shih Chen
-
Patent number: 5795725Abstract: Assays and antibodies are disclosed for the detection and quantitation of cardiac specific troponin I and troponin T in body fluids as an indicator of myocardial infarction. Since troponin I and T exist in various conformations in the blood, the ratios of the monomeric troponin I and T and the binary and ternary complexes may be related to the metabolic state of the heart. More specifically, immunoassays for determining the presence or amount of free, binary and ternary complexes of troponin I and T are claimed.Type: GrantFiled: April 18, 1995Date of Patent: August 18, 1998Assignee: Biosite Diagnostics IncorporatedInventors: Kenneth F. Buechler, Paul H. McPherson
-
Patent number: 5792606Abstract: The application describes homogeneous assays for determining ligands. A sample is contacted with a labeled substance P.sub.2 and receptor R. The receptor R consists of one molecule of P.sub.1, which monovalently and specifically binds to P.sub.2, and one molecule for R.sub.1, which binds to the ligand of interest. Complexes of P.sub.1, P.sub.2, R.sub.1 and ligand form, and are determined. R.sub.1 must be a nucleic acid molecule.Type: GrantFiled: May 5, 1995Date of Patent: August 11, 1998Assignee: Boehringer Mannheim GmbHInventors: Arno Deger, Roland Schenk
-
Patent number: 5792617Abstract: A test kit and method for the highly sensitive detection of specific analytes in a sample is provided. The presence of the analyte in the sample results in a decrease in the concentration of a growth inhibiting substance leading to proliferation of cells in the region of the analyte. The presence or absence of the analyte is determined by detecting the presence of increased numbers of cells. Assay sensitivity is accounted for by the exponential amplification of cell number that occurs during cell proliferation in the presence of analyte.Type: GrantFiled: June 7, 1995Date of Patent: August 11, 1998Inventor: M. Boris Rotman
-
Patent number: 5792620Abstract: Human pancreatic islet cell glutamic acid decarboxylase (GAD), an autoantigen involved in the development of insulin-dependent diabetes mellitus (IDDM), has been cloned, sequenced and expressed by recombinant means. Recombinant human islet cell GAD polypeptides and antibodies specific to the GAD polypeptides can be used in methods of diagnosis and treatment, including use in immunoadsorptive therapy and the induction of immune tolerance.Type: GrantFiled: August 17, 1993Date of Patent: August 11, 1998Assignees: The Board of Regents of the University of Washington, ZymoGenetics, Inc.Inventors: Ake Lernmark, Allan E. Karlsen, Catherine E. Grubin, William Hagopian, Patrick J. O'Hara, Donald C. Foster
-
Patent number: 5789185Abstract: The subject invention concerns a novel selective, sensitive, and highly reliable immunoassay for detecting human IL-1.beta. in cultured mononuclear cells or human body fluids. It is a sandwich immunoassay which is useful in diagnostic work to detect IL-1.beta. selectively, for the first time, from among similar lymphokines and other substances known to interfere with bioassays for IL-1.Type: GrantFiled: December 11, 1995Date of Patent: August 4, 1998Assignee: Cistron Biotechnology, Inc.Inventor: Peter J. Lisi
-
Patent number: 5789163Abstract: This invention discloses novel immunoassay termed an ELONA, employing nucleic acid ligands as capture molecules and/or detector molecules.Type: GrantFiled: June 7, 1995Date of Patent: August 4, 1998Assignee: NeXstar Pharmaceuticals, Inc.Inventors: Dan W. Drolet, Sumedha D. Jayasena, Larry Gold
-
Patent number: 5789152Abstract: The present invention encompasses membranous baculovirus-derived vesicle compositions having exposed on their external surfaces a ligator capable of selectively binding a ligand to be detected. The compositions also have exposed on their outer surfaces a signal reagent capable of reacting with another signal reagent to generate a signal capable of being detected. The present invention also encompasses assay methods for determining the presence and amount of a ligand in a sample using the membranous vesicle compositions of the present invention.Type: GrantFiled: March 16, 1994Date of Patent: August 4, 1998Assignee: Basil T. HoneInventors: Christopher Black, Pierre-Francios Tosi, Andrew Atkin, Jaime E. Lazarte, Yves Claude Nicolau
-
Patent number: 5786156Abstract: The present invention relates to peptides immunoreactive with anti-apolipoprotein(a) antibodies and to their use in raising monoclonal and polyclonal antibodies, in immunoassays and of their corresponding oligonucleotides as probes and primers in nucleic acid methodology.Type: GrantFiled: June 27, 1994Date of Patent: July 28, 1998Assignee: PerImmune Holdings, Inc.Inventors: W. C. Taddei-Peters, Sandra M. Butler
-
Patent number: 5786160Abstract: A novel natural killer cell-specific molecule, designated as PEN5, consisting essentially of a glycoprotein pair called PEN5.alpha. and PEN5.beta., having apparent molecular weights of 120-150 and 210-245 kdal, respectively. Monoclonal antibodies, including immunoreactive fragments and derivatives thereof, that bind to unique epitopes present on this NK cell-specific molecule; hybridomas that produce the monoclonal antibodies; methods of using the antibodies and fragments and derivatives; and methods for detecting and/or removing natural killer cells from a sample containing a mixed population of cells are also provided.Type: GrantFiled: June 7, 1995Date of Patent: July 28, 1998Assignee: Dana-Farber Cancer InstituteInventors: Paul Anderson, Eric Vivier
-
Patent number: 5783401Abstract: A device for detecting the presence of substances, particularly biological materials, contained in a liquid sample is formed of a series of layers of film materials. A first film has a cut-out which forms an upper reservoir for receiving the liquid sample. A first reagent is provided in the upper reservoir capable of reacting with a substance possibly contained in the liquid sample. A first membrane is situated at the base of the upper reservoir and is made of a material which is temporarily impermeable so that the liquid sample is temporarily retained in the upper reservoir in contact with the first reagent, but after awhile the membrane becomes permeable and allows the liquid to pass. A second film has a cut-out which forms a median reservoir positioned for receiving the liquid passing through the first membrane. A second reagent is provided in the median reservoir capable of reacting with a predetermined substance.Type: GrantFiled: July 1, 1994Date of Patent: July 21, 1998Assignee: Quidel CorporationInventor: Jacques Toledano
-
Patent number: 5783397Abstract: A method in which natural sample components are simultaneously fractionated and screened for compounds that bind tightly to specific molecules of interest is disclosed. Such newly isolated ligands are good candidates for potential therapeutic or diagnostic compounds. The natural sample is first combined with a potential target molecule and then subjected to capillary electrophoresis (CE). Charged (or even neutral) compounds present in the natural sample that bind to the added target molecule can alter its normal migration time upon CE, by changing its charge-to-mass ratio, or will cause a variation in peak shape or area. Complex formation can be detected by simply monitoring the migration of the target molecule during electrophoresis. Any new ligands that bind to the target molecule will be good candidates for therapeutic or diagnostic compounds. Interfering, weak-binding ligands commonly present in crude extracts are not detected.Type: GrantFiled: June 12, 1996Date of Patent: July 21, 1998Assignee: Northeastern UniversityInventors: Dallas E. Hughes, Barry L. Karger
-
Patent number: 5783453Abstract: The assay described herein is predicated on an observation that when acridinium ester labeled tracers are bound to their corresponding binding conjugate immobilized on a metal oxide solid phase, the measurable chemiluminescent light emission of the labeled tracer bound to the solid phase is quenched as compared to the free fraction tracer that is unattached to the solid phase. According to the invention, a non-separation specific binding assay to detect or quantify the presence of an analyte is provided where the entire reaction mixture is flashed (including unreacted tracer) and modulated signal (because of the quench effect) is associated with a reference, thus determining the amount or presence of said analyte in said sample. Disadvantages inherent in heterogeneous assays employing multiple separations may be avoided using this non-separation method.Type: GrantFiled: June 29, 1995Date of Patent: July 21, 1998Assignee: Chiron Diagnostics CorporationInventors: Eve H. Barlow, Eddie Carroll, III, Joseph E. Connolly, Michael J. Lee, Richard A. Martinelli, John T. Unger
-
Patent number: 5780247Abstract: Two or more analytes having the same action, or having different actions in spite of their similar structures, or two or more analytes having the same action and the same detectable chemical characteristics, in samples derived from living bodies, etc., can be measured rapidly and easily by forming one or more complexes with one or more affinity substances, separating the complexes by using high pressure liquid chromatography, followed by measurement of the amount of an affinity substance or one of the analytes.Type: GrantFiled: June 7, 1995Date of Patent: July 14, 1998Assignee: Wako Pure Chemical Industries, Ltd.Inventors: Shinji Satomura, Kenji Nakamura, Shuji Matuura
-
Patent number: 5780239Abstract: Method for detecting casts in urine by measuring Tamm-Horsfall protein by solid and liquid phase reagents including a method for manufacturing a enzyme specific for Tamm-Horsfall protein which produces a detectable response in the presence of casts in urine.Type: GrantFiled: July 2, 1996Date of Patent: July 14, 1998Inventors: Jesse M. Carter, Jack V. Smith
-
Patent number: 5780249Abstract: Chemiluminescent electron-rich aryl-substituted 1,2-dioxetane compounds are disclosed in which the aryl group is poly-substituted with suitable electron-donating groups such that the light-emitting pattern of the molecule results in a very high luminescent count, thus providing for a sensitive and precise assay for haptens, analytes, polynucleotides and the like. These substituted aryl-containing 1,2-dioxetane compounds can be used as direct labels in an immunoassay or when derivatized with an appropriate leaving group, can be used as a substrate for a enzyme immunoassay. The unusual chemiluminescence of the compounds allows the timing of the luminescent reaction to be exactly controlled.Type: GrantFiled: May 9, 1995Date of Patent: July 14, 1998Assignee: Abbott LaboratoriesInventors: Nai-Yi Wang, Roger C. Hu
-
Patent number: 5780243Abstract: The invention comprises a low temperature method for the in situ derivatization and coupling of thermally and hydrolytically labile organic compounds such as spectinomycin to immunogenic carrier substances. The compound coupled to the immunogenic carrier is utilized to produce antibodies selective for the organic compound. Such methods allow for the quantitative analysis of the target organic compound and may be competitive or non-competitive immunoassays in which the dose response is directly or indirectly proportional to the concentration of spectinomycin-related substances. Such assays may be used to detect the presence of or to quantitate the amount of the organic compound in a complex and varied immunological background such as a sample of a biomass material. Detection of organic compound in the sample occurs through binding to a specific antibody.Type: GrantFiled: June 28, 1996Date of Patent: July 14, 1998Assignee: Thaco Research, Ltd.Inventor: James D. Thacker
-
Patent number: 5776671Abstract: Influenza virus-infected cells secrete .alpha.-N-acetylgalactosaminidase into the blood stream, resulting in the deglycosylation of the Gc protein. This inactivates the MAF precursor activity of the Gc protein, leading to immunosuppression. Thus, the .alpha.-N-acetylgalactosaminidase activity in a patient's bloodstream can serve as a diagnostic and prognostic index. Antibody-sandwich ELISA method and kits for influenza virus specific .alpha.-N-acetylgalactosaminidase as an antigen were developed to detect serum or plasma .alpha.-N-acetylgalactosaminidase activity in influenza infected patients and are used as a diagnostic/prognostic index.Type: GrantFiled: September 26, 1997Date of Patent: July 7, 1998Inventor: Nobuto Yamamoto
-
Patent number: 5776703Abstract: There is provided an assay of enhanced sensitivity for the qualitative and quantitative determination of haptens. These may be assayed entities such as antigens, antibodies, a wide variety of biologically active proteins. The novel assay of increased sensitivity is based on the formation of a complex of the entity to be measured with another entity, tagging this conjugate with a oxidizing entity, reacting the resultant entity with a redox substrate to form a product which is photosensitive and irradiating same thus enhancing the sensitivity of the assay. Colored or fluorescent products give highly sensitive results. According to a preferred embodiment the oxidized entity is reacted with a non-ionic detergent, enhancing the resulting fluorescence.Type: GrantFiled: March 2, 1995Date of Patent: July 7, 1998Inventor: Seymon Bystryak
-
Patent number: 5776674Abstract: An optical trap is used to translate a particle through a thin film coating on an optically-flat surface. Preferably, the thin film coating is heterogeneous and the optical trap is used to move the particle through a succession of different regions of the thin film coating where different chemical, biochemical and/or biological processes take place. Examples of chemical, biochemical and/or biological processes that might be implemented in accordance with the invention include the following: oligonucleotide synthesis and sequencing, peptide synthesis and sequencing, carbohydrate synthesis and sequencing, combinatorial library synthesis and screening, conventional (i.e., Sanger or Maxam-Gilbert) DNA sequengcing, or single-molecule DNA sequencing. In one embodiment of the invention, reaction products are left behind as the particle is moved through the thin film coating. Advantageously, these products can be identified by suitable means.Type: GrantFiled: June 5, 1995Date of Patent: July 7, 1998Assignee: SEQ, LtdInventor: Kevin M. Ulmer
-
Patent number: 5776487Abstract: The present invention relates to the detection of a variety of analytes in a patient sample employing liposomes with associated ligand, where the ligand is capable of binding target analyte in that sample. In another aspect of the invention, the assays employ liposomes as a soluble support matrix where at least a portion of the support is associated with the ligand and the ligand is in a confirmation permitting it to bind to target analyte in a patient sample.Type: GrantFiled: April 19, 1996Date of Patent: July 7, 1998Assignee: Pasteur Sanofi DiagnosticsInventors: Nancy Maxfield Wilson, Catherine Larue
-
Patent number: 5773232Abstract: A method for measuring the responses of sets or subsets of lymphocytes to mitogens or antigens in a sample is disclosed comprising incubating a population of cells with a mitogen or antigen, separating the desired subset of cells by means of the interaction of a specific binding reagent that is attached to the solid phase with a cell surface determinant that is present on the cell subset of interest, lysing the separated cells, and measuring an intracellular component that is increased if the cells have responded to the stimulus. The method provides a convenient, simple, and reliable method for measuring immune function in a variety of conditions.Type: GrantFiled: September 12, 1997Date of Patent: June 30, 1998Assignee: Biotechnology Transfer, Inc.Inventor: Majorie L. Wier
-
Patent number: 5773226Abstract: The invention relates to isolated nucleic acids encoding recombinant calf intestinal alkaline phosphatase. Expression vectors and host cells transformed or transfected with such vectors are also provided. The invention further provides multifunctional polypeptides containing amino acid sequences encoding for calf intestinal alkaline phosphatase and a second amino acid sequence encoding a reagent having specific reactivity with a ligand. The recombinant calf intestinal alkaline phosphatase or its active fragments and the multifunctional polypeptides can be used in the methods for determining the presence or concentration of a ligand.Type: GrantFiled: June 2, 1995Date of Patent: June 30, 1998Assignee: La Jolla Cancer Research FoundationInventor: Jose L. Millan
-
Patent number: 5773222Abstract: A solid phase method of detection or assay of the presence or amount in a serum or plasma sample of a target antibody specific to a cell surface antigen. The sample is contacted with an immobilised preparation of cells bearing the antigen and antibody bound thereto is detected or assayed by means of an indicator comprising a binding partner for the antibody bound to labelled latex particles.Type: GrantFiled: January 11, 1995Date of Patent: June 30, 1998Assignee: National Blood AuthorityInventor: Marion Lesley Scott
-
Patent number: 5770377Abstract: A method for interfering with the binding between p53 and MDM2 or a protein having a p53 binding site analogous to that of MDM2, which method comprises administering a effective amount of a compound, selected from the group consisting of a peptide having up to twenty eight amino acids which is able to disrupt or prevent binding between p53 and MDM2, or a functional peptide analogue thereof.Compounds for use in the method, methods for detecting such compounds and their application in the diagnosis and treatment of tumours is also described and claimed.Type: GrantFiled: April 19, 1995Date of Patent: June 23, 1998Assignee: University of DundeeInventors: Steven Michael Picksley, David Philip Lane
-
Patent number: 5770388Abstract: Methods are disclosed for separating a component of interest from a mixture containing the component of interest and other components. The method comprises contacting a first liquid medium containing the component of interest and other components with a second liquid medium that is of different density than and/or of different viscosity than the first liquid medium. The contact is carried out in such a way that mixing of the media is minimized or avoided. The component of interest is bound to magnetic particles. The contacted first liquid medium and second liquid medium are subjected to a magnetic field gradient to allow the magnetic particles to migrate into the second liquid medium and separation of the component of interest from other components is realized. Also disclosed are assays employing the present method. Kits for carrying out the present method and assays are also disclosed.Type: GrantFiled: December 13, 1993Date of Patent: June 23, 1998Assignee: Dade Behring Marburg GmbHInventor: John Vorpahl
-
Patent number: 5770721Abstract: This method for preparing micromatrices consists in applying a specially-patterned intermediate layer of laser-absorbing substance on a solid support. The configuration of the sublayer fully corresponds to the topology of the manufactured matrix. The intermediate layer is further covered by a continuous layer of gel , the gel and the material of the support being transparent towards laser radiation. The gel layer is irradiated by a laser beam for a time needed to evaporate simultaneously the gel in the places immediately above the laser-absorbing sublayer and the sublayer itself. Oligonucleotides from a chosen set are then attached to the formed gel `cells`, one oligonucleotide to each cell.This method is intended for use in biotechnology, specifically for deciphering the nucleotide sequence of DNA.Type: GrantFiled: May 19, 1995Date of Patent: June 23, 1998Assignee: University of ChicagoInventors: Gennady Moiseevich Ershov, Andrei Darievich Mirzabekov
-
Patent number: 5770385Abstract: Antibodies made to a flanking region GPR(31-98) in human gastrin-releasing peptide (GRP) precursor. Since the antibodies have high affinity to GRP precursor, and the GPR precursor is highly stable in the blood, then lung cancer, especially small cell lung cancer can be diagnosed with high reliability by detecting or measuring GRP precursor in the blood of a patient using the present antibodies.Type: GrantFiled: May 17, 1996Date of Patent: June 23, 1998Assignees: Tonen Corporation, Terumo CorporationInventors: Ken Yamaguchi, Yoshio Miyake
-
Patent number: 5770176Abstract: Methods and test kits for detecting, or detecting and quantitating functional nuclear receptors in cell or tissue samples are disclosed. Such methods provide highly sensitive assays requiring small sample sizes and short turnaround times. The methods are useful in developing prognoses and/or treatment programs for cancer patients, especially in determining whether therapy to interfere with the receptor's activation of gene transcription, such as, endocrine therapy, would be helpful.Type: GrantFiled: December 8, 1995Date of Patent: June 23, 1998Assignee: Chiron Diagnostics CorporationInventor: Ruhangiz Dokhi Nargessi
-
Patent number: 5766867Abstract: Novel nucleic acids, proteins, peptides, antigens, and antibodies related to non-A, non-B hepatitis, and non-A, non-B hepatitis diagnostic reagents using those materials.Type: GrantFiled: February 23, 1995Date of Patent: June 16, 1998Assignee: Immuno Japan Inc.Inventors: Shunji Mishiro, Tetsuo Nakamura
-
Patent number: 5763174Abstract: The present invention provides novel human polynucleotide sequences and the recombinant human DRADA proteins encoded thereby and methods of use thereof.Type: GrantFiled: November 13, 1995Date of Patent: June 9, 1998Assignee: The Wistar Institute of Anatomy & BiologyInventor: Kazuko Nishikura
-
Patent number: 5763164Abstract: The present invention relates to tumor specific antigens and functional proteins of a tumor cell preparable by identifying protein presents in the tumor cell that are selectively immunogenic for tumor patients. The present invention still further provides a process of making a peptide library of tumor specific humoral antigens, a process of increasing the immunogenic specificity of a tumor-associated antigen, an assay kit for detecting the presence of an antibody immunoreactive with a tumor-specific antigen, and a process of making T cells sensitized to a tumor-specific antigen.Type: GrantFiled: February 3, 1994Date of Patent: June 9, 1998Assignee: Northwestern UniversityInventor: Emanuel Calenoff
-
Patent number: 5763195Abstract: The complete amino acid and nucleotide sequence for adenylate cyclase stimulating factor is provided, thereby facilitating the synthesis of ACSF in recombinant cell culture. ACSF amino acid sequence variants and ACSF antibodies are provided which are useful in the treatment of humoral hypercalcemia of malignancy or in immunoassays for ACSF. In particular, antibodies capable of binding only the C-terminal domains of ACSF are useful in immunoassays for ACSF which avoid interference by parathyroid hormone. Also provided are novel polypeptides selected from the group of the ACSF basic peptide, the ACSF C-terminal peptide, or the ACSF domain containing both of the basic and C-terminal peptides.Type: GrantFiled: April 20, 1995Date of Patent: June 9, 1998Assignees: Genentech, Inc., University of MelbourneInventors: William I. Wood, Thomas John Martin, Larry John Suva
-
Patent number: 5759791Abstract: A method of determining the prognosis of a solid tumor is provided, in which a sample from a patient bearing a tumor is assayed for the presence of a protein which is immunologically cross-reactive with the hr gene product, but not with haptoglobin 1 or haptoglobin 2. Also provided is a method for preparing antibodies specific for this diagnostic marker which correlates with early relapse and metastasis of breast and other cancers. The marker can be detected using immunological methods employing antibodies specific for Hpr protein and not cross-reactive with haptoglobins 1 or 2.Type: GrantFiled: January 24, 1994Date of Patent: June 2, 1998Assignee: The Johns Hopkins UniversityInventors: Francis P. Kuhajda, Gary R. Pasternack
-
Patent number: 5756361Abstract: A method of screening for the presence of a periodontal disease condition is disclosed. The method involves obtaining an oral fluid sample from a human subject being tested, and determining the level of native free pyridinium crosslinks (free pyridinoline and/or free deoxypyridinoline) from the subject. An above-normal level of crosslinks, when compared with a predetermined level characteristic of normal subjects, is an indication of the presence of a periodontal disease condition.Type: GrantFiled: September 8, 1994Date of Patent: May 26, 1998Assignee: Metra Biosystems, Inc.Inventors: Neil Winterbottom, Viola T. Kung, Baltazar Gomez, F. Michael Eggert
-
Patent number: 5756126Abstract: The present invention provides a dry solid medium for storage of genetic material, including RNA and DNA, in a form suitable for subsequent analysis. The invention also provides a dry solid medium including components which function in subsequent analysis of the genetic material using, for example, PCR, reverse transcriptase initiated PCR, LCR, RFLP, or genetic hybridization. The components for subsequent analysis include, for example, nucleotide sequences such as a primer and a target sequence stabilizer. The invention further provides methods for using the dry solid medium of the invention. The invention and methods thereof are particularly suited for analysis in automated systems.Type: GrantFiled: June 7, 1995Date of Patent: May 26, 1998Assignee: Flinders Technologies Pty. Ltd.Inventor: Leigh Alexander Burgoyne
-
Patent number: 5753436Abstract: A chemiluminescent assays for the determination of the presence or amount of a biopolymer in bound assays using 1,2-dioxetanes in connection with AttoPhos.TM. as chemiluminescent substrates for enzyme-labeled targets or probes is provided. Further disclosed is a kit for conducting a bioassay for the presence or concentration of a biopolymer comprising a) an enzyme complex; b) a 1,2-dioxetane; and c) AttoPhos.TM..Type: GrantFiled: March 9, 1995Date of Patent: May 19, 1998
-
Patent number: 5753441Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics.Type: GrantFiled: January 5, 1996Date of Patent: May 19, 1998Assignees: Myriad Genetics, Inc., University of Utah Research Foundation, The United States of America as represented by the Department of Health and Human ServicesInventors: Mark H. Skolnick, David E. Goldgar, Yoshio Miki, Jeff Swenson, Alexander Kamb, Keith D. Harshman, Donna M. Shattuck-Eidens, Sean V. Tavtigian, Roger W. Wiseman, P. Andrew Futreal
-
Patent number: 5753450Abstract: Compositions and methods are provided which are useful in determining the levels of the C-telopeptide of human Type I collagen. The levels of the C-telopeptide are used as a marker of collagen degradation in an individual, and thus serve as a sensitive and specific indicator of bone resorption. Assays for the C-telopeptide find a variety of uses, including use in diagnosing metabolic bone disorders such as osteoporosis or postmenopausal rapid bone losers, monitoring the efficacy of therapeutic regimens designed to treat such disorders, determining the extent of imbalances between bone formation and resorption.Type: GrantFiled: June 7, 1995Date of Patent: May 19, 1998Inventor: David J. Baylink
-
Patent number: 5750357Abstract: A detectable synthetic copolymer useful to detect the presence of a microorganism in a test sample is provided. The copolymer comprises repeating monomeric units, which incorporate a population of first monomeric units each comprising a binding agent which binds to a microorganism having multiple binding sites for said binding agent and which further incorporates a population of a second monomeric units each comprising a detectable label or a binding site for a detectable label.Type: GrantFiled: January 30, 1995Date of Patent: May 12, 1998Assignee: MicroQuest Diagnostics, Inc.Inventors: Alan D. Olstein, Richard Albert
-
Patent number: 5750355Abstract: The invention is directed to methods and kits for detecting and measuring the presence or absence of perinuclear anti-neutrophil cytoplasmic autoantibody of ulcerative colitis or primary sclerosing cholangitis. The methods and kits of the present invention provide safe and reliable means for diagnosing ulcerative colitis and primary sclerosing cholangitis. The antigens reactive with perinuclear anti-neutrophil cytoplasmic autoantibody of ulcerative colitis and primary sclerosing cholangitis are also provided.Type: GrantFiled: October 7, 1994Date of Patent: May 12, 1998Assignee: Cedars-Sinai Medical CenterInventors: Stephan R. Targan, Alda Vidrich
-
Patent number: 5747296Abstract: Compositions enriched for Neutrophil Inhibitory Factor which inhibit neutrophil activity including adhesion to vascular endothelial cells are provided. Also provided are recombinant Neutrophil Inhibitory Factors which also which inhibit neutrophil activity. Such compositions may comprise a glycoprotein isolated from nematodes. These compositions and recombinant Neutrophil Inhibitory Factors are useful in the therapy of conditions which involve abnormal or undesired inflammatory responses.Type: GrantFiled: December 23, 1993Date of Patent: May 5, 1998Assignee: Corvas International, Inc.Inventors: Matthew Moyle, David L. Foster, George P. Vlasuk
-
Patent number: 5747250Abstract: A therapeutic or diagnostic agent according to the invention contains as active substance at least one nucleic acid which hybridizes with a Pax gene or at least one Pax protein or at least one antibody against a Pax protein or a derivative thereof. The agents according to the invention are used in tumour diagnosis or/and tumour therapy as well as an antisense nucleic acid for the inhibition of gene expression.Type: GrantFiled: March 27, 1995Date of Patent: May 5, 1998Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.Inventors: Peter Gruss, Catharina Maulbecker
-
Patent number: 5747260Abstract: A method of prognosing a head-injured subject or a subject who may be at risk of sustaining a head injury for the likelihood that a head injury might give rise to a chronic neurodegenerative pathology which could result in neuropsychological, psychiatric or neurological deficits, the method comprising detecting the presence or absence of ApoE isoforms or of DNA encoding ApoE isoforms in the subject.Type: GrantFiled: February 25, 1997Date of Patent: May 5, 1998Assignee: SmithKline Beecham p.l.c.Inventors: Gareth Wyn Roberts, David Ian Graham, James Alan Ramsey Nicoll
-
Patent number: 5747266Abstract: An assay and method for screening newborns to determine risk of Sudden Infant Syndrome is described. The assay and method is based on the detection of elevated IgM-anti-IgG (MAG) levels in newborns' serum within the first year of birth. In particular, it has been discovered that elevated MAG levels indicate an increased risk of Sudden Infant Death Syndrome (SIDS).Type: GrantFiled: September 16, 1996Date of Patent: May 5, 1998Inventor: Peter G. Beach
-
Patent number: 5747242Abstract: A variant of a LAV virus, designated LAV.sub.ELI and cable of causing AIDS. The cDNA and antigens of the LAV.sub.ELI virus can be used for the diagnosis of AIDS an pre-AIDS.Type: GrantFiled: June 6, 1995Date of Patent: May 5, 1998Assignee: Institut PasteurInventors: Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Luc Montagnier